Polymorphisms in dopamine receptors: what do they tell us?

Wong, Albert H.C.; Buckle, Chris; Tol, Hubert H.M. Van

doi:10.1016/s0014-2999(00)00815-3

Cited by 148 publications

(21 citation statements)

References 263 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While inactivating polymorphisms of the D 5 receptor have been reported, the coding region of the D 1 receptor has no polymorphisms that result in a change in amino acid [38]. A polymorphism in the non-coding region of the D 1 receptor (A-48G) has been reported to be associated with essential hypertension in a Japanese population [39]but its role in the regulation of D 1 receptor gene in normotensive or hypertensive states remains to be established.…”

Section: Classification Of Dopamine Receptorsmentioning

confidence: 99%

Regulation of Blood Pressure by Dopamine Receptors

José

Eisner²,

Felder³

2003

Nephron Physiol

View full text Add to dashboard Cite

Dopamine is an important regulator of blood pressure. Its actions on renal hemodynamics, epithelial transport and humoral agents such as aldosterone, catecholamines, endothelin, prolactin, pro-opiomelanocortin, renin and vasopressin place it in central homeostatic position for regulation of extracellular fluid volume and blood pressure. Dopamine also modulates fluid and sodium intake via actions in the central nervous system and gastrointestinal tract, and by regulation of cardiovascular centers that control the functions of the heart, arteries and veins. Abnormalities in dopamine production and receptor function accompany a high percentage of human essential hypertension and several forms of rodent genetic hypertension. Some dopamine receptor genes and their regulators are in loci linked to hypertension in humans and in rodents. Furthermore, single nucleotide polymorphisms (SNPs) of genes that regulate dopamine receptors, alone or via the interaction with SNPs of genes that regulate the renin-angiotensin system, are associated with human essential hypertension. Each of the five dopamine receptor subtypes (D₁, D₂, D₃, D₄ and D₅) participates in the regulation of blood pressure by mechanisms specific for the subtype. Some receptors (D₂ and D₅) influence the central and/or peripheral nervous system; others influence epithelial transport and regulate the secretion and receptors of several humoral agents (e.g., the D₁, D₃ and D₄ receptors interact with the renin-angiotensin system). Modifications of the usual actions of the receptor can produce blood pressure changes. In addition, abnormal functioning of these dopamine receptor subtypes impairs their antioxidant function.

show abstract

Section: Classification Of Dopamine Receptorsmentioning

confidence: 99%

Regulation of Blood Pressure by Dopamine Receptors

José

Eisner²,

Felder³

2003

Nephron Physiol

View full text Add to dashboard Cite

show abstract

“…Several variants of DR genes have been detected, and their role has been characterized in Alzheimer’s disease, schizophrenia, bipolar disorder, and addiction [7,8,9]. Work from our group showed that the TT genotype at DRD1 rs686 may predispose PD patients to developing visual hallucinations (VHs) while subjects with GG at DRD1 rs4532 display a shorter time to VHs [10].…”

Section: Introductionmentioning

confidence: 99%

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease

Comi

Ferrari

Marino

et al. 2017

IJMS

View full text Add to dashboard Cite

L-dopa–induced dyskinesia (LID) is a frequent motor complication of Parkinson’s disease (PD), associated with a negative prognosis. Previous studies showed an association between dopamine receptor (DR) gene (DR) variants and LID, the results of which have not been confirmed. The present study is aimed to determine whether genetic differences of DR are associated with LID in a small but well-characterized cohort of PD patients. To this end we enrolled 100 PD subjects, 50 with and 50 without LID, matched for age, gender, disease duration and dopaminergic medication in a case-control study. We conducted polymerase chain reaction for single nucleotide polymorphisms (SNP) in both D1-like (DRD1A48G; DRD1C62T and DRD5T798C) and D2-like DR (DRD2G2137A, DRD2C957T, DRD3G25A, DRD3G712C, DRD4C616G and DRD4nR VNTR 48bp) analyzed genomic DNA. Our results showed that PD patients carrying allele A at DRD3G3127A had an increased risk of LID (OR 4.9; 95% CI 1.7–13.9; p = 0.004). The present findings may provide valuable information for personalizing pharmacological therapy in PD patients.

show abstract

“…1999; Wong et al. 2000; Ritchie and Noble 2003). Therefore, due to being implicated in combat‐related psychopathology in aging veterans, DRD2 is a good candidate to investigate the genetic contribution to PTSD traumatic stress conditions in active‐duty service members.…”

Section: Introductionmentioning

confidence: 99%

Brain‐derived neurotropic factor polymorphisms, traumatic stress, mild traumatic brain injury, and combat exposure contribute to postdeployment traumatic stress

et al. 2015

View full text Add to dashboard Cite

BackgroundIn addition to experiencing traumatic events while deployed in a combat environment, there are other factors that contribute to the development of posttraumatic stress disorder (PTSD) in military service members. This study explored the contribution of genetics, childhood environment, prior trauma, psychological, cognitive, and deployment factors to the development of traumatic stress following deployment.MethodsBoth pre‐ and postdeployment data on 231 of 458 soldiers were analyzed. Postdeployment assessments occurred within 30 days from returning stateside and included a battery of psychological health, medical history, and demographic questionnaires; neurocognitive tests; and blood serum for the D2 dopamine receptor (DRD2), apolipoprotein E (APOE), and brain‐derived neurotropic factor (BDNF) genes.ResultsSoldiers who screened positive for traumatic stress at postdeployment had significantly higher scores in depression (d = 1.91), anxiety (d = 1.61), poor sleep quality (d = 0.92), postconcussion symptoms (d = 2.21), alcohol use (d = 0.63), traumatic life events (d = 0.42), and combat exposure (d = 0.91). BDNF Val66 Met genotype was significantly associated with risk for sustaining a mild traumatic brain injury (mTBI) and screening positive for traumatic stress. Predeployment traumatic stress, greater combat exposure and sustaining an mTBI while deployed, and the BDNF Met/Met genotype accounted for 22% of the variance of postdeployment PTSD scores (R 2 = 0.22, P < 0.001). However, predeployment traumatic stress, alone, accounted for 17% of the postdeployment PTSD scores.ConclusionThese findings suggest predeployment traumatic stress, genetic, and environmental factors have unique contributions to the development of combat‐related traumatic stress in military service members.

show abstract

Polymorphisms in dopamine receptors: what do they tell us?

Cited by 148 publications

References 263 publications

Regulation of Blood Pressure by Dopamine Receptors

Regulation of Blood Pressure by Dopamine Receptors

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease

Brain‐derived neurotropic factor polymorphisms, traumatic stress, mild traumatic brain injury, and combat exposure contribute to postdeployment traumatic stress

Contact Info

Product

Resources

About